<DOC>
	<DOCNO>NCT01727934</DOCNO>
	<brief_summary>The purpose open-label study ass safety , antiviral activity , pharmacokinetics 9 subcutaneous injection miravirsen monotherapy ( 5 weekly dos 5 week , follow 4 dos every week 7 week ) total 12 week treatment . The subject enrol study chronically infect HCV genotype 1 null responder treatment peg IFNÎ±/RBV therapy .</brief_summary>
	<brief_title>Miravirsen Study Null Responder Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Diagnosis chronic hepatitis C HCV genotype 1 BMI 1838 kg/m2 Null responder pegylated interferon alpha ribavirin Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Significant liver disease addition hepatitis C Decompensated liver disease medical history current clinical feature Histologic evidence hepatic cirrhosis Concurrent clinically significant medical diagnosis ( CHC ) Concurrent social condition ( e.g . drug abuse , alcohol excess , poor live accommodation ) Clinically significant illness within 30 day precede entry study Participated investigational drug study within 30 day 5 halflives , whichever longer , prior start study medication History clinically significant allergic drug reaction</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Antisense</keyword>
	<keyword>miR-122 antagonist</keyword>
	<keyword>host factor</keyword>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>